Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 16, Pages 3951
Publisher
MDPI AG
Online
2019-08-15
DOI
10.3390/ijms20163951
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
- (2019) Anna Rachiglio et al. Cancers
- Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib
- (2019) Xuanxuan Zheng et al. LUNG CANCER
- The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
- (2019) Marzia Del Re et al. BMC CANCER
- Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib
- (2019) Liang Zeng et al. Journal of Thoracic Oncology
- Barcode sequencing identifies resistant mechanisms to EGFR ‐inhibitors in circulating tumor DNA of lung cancer patients
- (2019) Satoru Kitazono et al. CANCER SCIENCE
- Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification
- (2018) L Liu et al. ANNALS OF ONCOLOGY
- Worldwide Frequency of Commonly Detected EGFR Mutations
- (2018) Rondell P. Graham et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Exosomes in lung cancer diagnosis and treatment. From the translating research into future clinical practice
- (2018) Christos Masaoutis et al. BIOCHIMIE
- PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
- (2018) Marzia Del Re et al. BRITISH JOURNAL OF CANCER
- Plasma exosome levels in non-small-cell lung cancer: Correlation with clinicopathological features and prognostic implications
- (2018) Qingyun Liu et al. Cancer Biomarkers
- Liquid Biopsy in Tumor Genetic Diagnosis
- (2018) Andreas Jung et al. Deutsches Arzteblatt International
- Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
- (2018) Dana Wai Yi Tsui et al. EMBO Molecular Medicine
- Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR -Mutated NSCLC
- (2018) Anna Buder et al. Journal of Thoracic Oncology
- Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR -Mutated NSCLC
- (2018) Roberta Minari et al. Journal of Thoracic Oncology
- Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib
- (2018) Yubo Wang et al. LUNG CANCER
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
- (2018) R. Minari et al. LUNG CANCER
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance
- (2018) Stefano Fogli et al. PHARMACOGENOMICS
- Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA
- (2018) Davina Gale et al. PLoS One
- Exosome‑mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR‑21
- (2018) Changwen Jing et al. Oncology Letters
- Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
- (2018) Jan Nyrop Jakobsen et al. Oncotarget
- MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
- (2018) Kiichiro Ninomiya et al. Scientific Reports
- Prognostic role of circulating tumor cells in patients with EGFR -mutated or ALK -rearranged non-small cell lung cancer
- (2018) Bing Tong et al. Thoracic Cancer
- Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer
- (2018) Shaodong Hong et al. JAMA Oncology
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications
- (2018) Hongmei Zheng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition
- (2018) Lei Deng et al. Journal of Thoracic Oncology
- The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer
- (2018) Smadar Laufer-Geva et al. Journal of Thoracic Oncology
- C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
- (2018) Tobias Grabe et al. ACS Medicinal Chemistry Letters
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
- (2018) Francesco Passiglia et al. Scientific Reports
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
- (2018) V A Papadimitrakopoulou et al. ANNALS OF ONCOLOGY
- The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
- (2018) Marzia Del Re et al. BRITISH JOURNAL OF CANCER
- Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer
- (2018) Limin Niu et al. CANCER SCIENCE
- The role of circulating free DNA in the management of NSCLC
- (2018) Riziero Esposito Abate et al. Expert Review of Anticancer Therapy
- KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
- (2018) Kaori Nakatani et al. MOLECULAR CANCER THERAPEUTICS
- Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
- (2018) Maximilian J. Hochmair et al. Targeted Oncology
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
- (2018) Charu Aggarwal et al. JAMA Oncology
- Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
- (2018) Youjin Kim et al. Journal of Thoracic Oncology
- Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
- (2017) Zhen Wang et al. Journal of Thoracic Oncology
- Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
- (2017) Chao-Chi Ho et al. Journal of Thoracic Oncology
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer
- (2017) Surein Arulananda et al. Journal of Thoracic Oncology
- Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer
- (2017) Suzanne Jenkins et al. Journal of Thoracic Oncology
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
- (2017) Antonio Passaro et al. PHARMACOLOGICAL RESEARCH
- Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
- (2017) Marcin Skrzypski et al. Wspolczesna Onkologia-Contemporary Oncology
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- (2017) Ken Uchibori et al. Nature Communications
- Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
- (2017) Paolo Manca et al. Oncotarget
- Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
- (2017) Jing Xu et al. Oncotarget
- A Patient With Metastatic Lung Adenocarcinoma Harboring ConcurrentEGFRL858R,EGFRGermline T790M, andPIK3CAMutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer
- (2017) Philip E. Lammers et al. Journal of the National Comprehensive Cancer Network
- Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
- (2017) Bin Zou et al. Scientific Reports
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) S. Novello et al. ANNALS OF ONCOLOGY
- Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
- (2016) J. C. Thompson et al. CLINICAL CANCER RESEARCH
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment
- (2016) Jun Soo Ham et al. Journal of Thoracic Oncology
- A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
- (2016) Tony Shu Kam Mok et al. Journal of Thoracic Oncology
- Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma
- (2016) Greta Alì et al. Oncology Letters
- Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
- (2016) Ji Yun Lee et al. Oncotarget
- Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
- (2016) Marzia Del Re et al. Oncotarget
- Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
- (2016) Nicola Normanno et al. Oncotarget
- The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
- (2016) Shang-Gin Wu et al. Scientific Reports
- Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing
- (2016) Ke-Zhong Chen et al. Scientific Reports
- Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
- (2016) Antonio Passaro et al. Journal of Thoracic Disease
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- (2015) D. Planchard et al. ANNALS OF ONCOLOGY
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
- (2015) M. Soucheray et al. CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
- (2015) T. K. Sundaresan et al. CLINICAL CANCER RESEARCH
- Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
- (2015) C. P. Paweletz et al. CLINICAL CANCER RESEARCH
- Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy
- (2015) Daliang Qi et al. Journal of Cancer Research and Therapeutics
- Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
- (2015) Antonio Marchetti et al. Journal of Thoracic Oncology
- Mechanisms of Acquired Resistance to AZD9291
- (2015) Tae Min Kim et al. Journal of Thoracic Oncology
- Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
- (2015) Matthew G Oser et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
- (2015) Kenneth S. Thress et al. LUNG CANCER
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
- (2015) Z. Piotrowska et al. Cancer Discovery
- Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
- (2015) Kenichi Suda et al. Scientific Reports
- Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing
- (2014) Stephen Q Wong et al. BMC Medical Genomics
- Circulating Tumor DNA as a Liquid Biopsy for Cancer
- (2014) E. Heitzer et al. CLINICAL CHEMISTRY
- Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
- (2014) Marzia Del Re et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
- (2014) Friedhelm Bladt et al. Cancers
- Functions and Therapeutic Roles of Exosomes in Cancer
- (2014) Jacob A. Tickner et al. Frontiers in Oncology
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Genomic Medicine: New Frontiers and New Challenges
- (2013) M. D. Pasic et al. CLINICAL CHEMISTRY
- HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
- (2013) J. Hun Hah et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Tumor heterogeneity in the clinic: is it a real problem?
- (2013) Filip Janku Therapeutic Advances in Medical Oncology
- Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
- (2012) A. Passaro et al. CURRENT MEDICINAL CHEMISTRY
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient
- (2012) Vincent Fallet et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
- (2012) Ming-Hung Huang et al. Molecular Oncology
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
- (2011) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas
- (2010) Daisuke Matsubara et al. AMERICAN JOURNAL OF PATHOLOGY
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort
- (2009) Michèle Beau-Faller et al. Journal of Thoracic Oncology
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crosstalk in Met receptor oncogenesis
- (2009) Andrea Z. Lai et al. TRENDS IN CELL BIOLOGY
- The Met tyrosine kinase receptor in development and cancer
- (2008) Alessandra Gentile et al. CANCER AND METASTASIS REVIEWS
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started